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Hereditary haemochromatosis is autosomal recessive
disorder associated with the HLA-A locus on the
short arm of chromosome 6 [1]. It is the most
common genetic disorder worldwide [2]. About
56,000 babies are born each year with thalassaemia
major, of whom 30,000 require lifelong transfusions
to survive [3]. The disease is very prevalent in
European countries along the Mediterranean Sea and
in South East Asia. In other countries it becomes a
problem because of immigration from these areas.
Excessive iron deposition occurs mostly in the
pancreas, pituitary, but also in the heart. In normal
subjects, absorption of iron from the gut is inversely
correlated with iron stores. In homozygous hereditary
haemochromatosis there is increased absorption of
iron, which is not regulated by iron stores [4]. This
leads to progressive iron accumulation because there
is no normal mechanism for excretion of excess iron
once it has been absorbed into the body. The clinical
manifestations of iron overload include liver disease
in 75% of cases, weakness and lethargy in 74%, skin
hyperpigmentation in 70%, diabetes mellitus in 48%,
arthralgia in 44%, impotence in 45%, electrocardio-
graphic abnormalities in 31% and heart failure and
conduction disturbances in 15% [5, 6]. Heart failure
remains a major cause of death in these patients,
frequently people younger than 35 years [7]. In the
majority of patients iron induced cardiomyopathy can
be reversed by intense chelation therapy with desfer-
rioxamine and deferiprone [3, 8]. At this moment T2*
magnetic resonance imaging is the best way for early
detection of iron overload in patients with haemo-
chromatosis [9–11]. T2* is an unique magnetic
resonance parameter measured in milliseconds and
shortened in relation to the level iron in the heart. The
parameter can be used for screening haemochroma-
tosis patients and to guide chelation therapy in those
with established cardiac haemochromatosis [8]. The
paper of Mavrogeni et al. [12] in this issue of the
International Journal of Cardiac Imaging shows, that
heart failure patients with severe iron overload
indicated by a T2* value less than 10 ms had a
lower exercise capacity than patients with a T2*
value higher than 10 ms. The authors also show, that
there was a excellent relation of the extent of iron
overload measured by T2* and exercise tolerance in
thalassemia patients. As shown by others, thalassemia
patients present prolonged phase II on-transient
oxygen kinetics during submaximal, constant work-
load exercise, compared with healthy controls, pos-
sibly suggesting a slower rate of high energy
phosphate production and utilization and reduced
oxidative capacity of myocytes [13]. This could also
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DOI 10.1007/s10554-009-9538-yaccount for their signiﬁcantly limited exercise toler-
ance. Reduction of exercise tolerance is also s highly
associated with the limited functional status of
peripheral muscles in these patients [14]. This study
shows again that T2* MRI plays a crucial role in
screening cardiac haemochromatosis and guidance of
chelation therapy. Early detection of cardiac iron load
and early initiation of treatment are crucial for
survival of these patients. Recently the chelator
deferasirox has been shown to be more effective in
better at improving myocardial iron [15]. This could
improve outcome in thalassemia patients. As shown,
early effects of therapy can only be detected with
dedicated MRI sequences. Unfortunately these MRI
scanners are not always available in those areas,
where the prevalence of haemachromatosis patients is
extremely high.
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